Hematology-Oncologygenomic fusion breakpointsmeasurable residual disease
Genomic Fusion Breakpoints: A Breakthrough in Pediatric ALL MRD Monitoring
By MedXY|Apr 24, 2026
A novel genomic fusion breakpoint (GFB)-based MRD monitoring approach demonstrates superior sensitivity and specificity in pediatric ALL, addressing limitations of current IG/TCR-based methods, particularly in ETV6::RUNX1- and MEF2D-rearran
